Two years ago, the Food and Drug Administration marked a big step forward in the way doctors think about cancer: It approved Merck’s Keytruda to treat tumors that appear anywhere in the body, but are marked with a specific genetic signature.

But identifying such cancers, called MSI-High, for “microsatellite instability-high,” required a biopsy of a tumor that had been surgically removed. In a paper published Monday, Guardant Health, a biotechnology company, published results saying it can tell whether a patient’s cancer is MSI-High with a type of blood test, also known as a liquid biopsy.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.